Literature DB >> 17438060

Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.

Georgios Chamilos1, Russell E Lewis, Nathaniel Albert, Dimitrios P Kontoyiannis.   

Abstract

Paradoxical growth of some Candida isolates occurs at concentrations above the MIC for echinocandins. In 60 Candida bloodstream isolates from cancer patients (20 C. albicans isolates and 10 isolates each of C. parapsilosis, C. tropicalis, C. krusei, and C. glabrata), paradoxical growth was more frequent with caspofungin than micafungin or anidulafungin, was unrelated to MIC, and was strikingly absent in C. glabrata isolates.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17438060      PMCID： PMC1891358          DOI： 10.1128/AAC.00095-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

Review 2.  Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin.

Authors:  R E Gardiner; P Souteropoulos; S Park; D S Perlin
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

3.  Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Randall A Prince; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.

Authors:  Sevtap Arikan; Banu Sancak; Gulsen Hascelik
Journal:  Med Mycol       Date:  2005-03       Impact factor: 4.076

6.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.

Authors:  Varsha Moudgal; Tania Little; Dina Boikov; Jose A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

10.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226
View more
  66 in total

1.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 2.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.

Authors:  Aspasia Katragkou; Athanasios Chatzimoschou; Maria Simitsopoulou; Maria Dalakiouridou; Eudoxia Diza-Mataftsi; Chaido Tsantali; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

4.  The planarian Schmidtea mediterranea is a new model to study host-pathogen interactions during fungal infections.

Authors:  Eli Isael Maciel; Cen Jiang; Paul G Barghouth; Clarissa J Nobile; Néstor J Oviedo
Journal:  Dev Comp Immunol       Date:  2018-12-17       Impact factor: 3.636

5.  Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes.

Authors:  Mohamed Khlif; Hervé Bogreau; Annie Michel-Nguyen; Ali Ayadi; Stéphane Ranque
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

6.  In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.

Authors:  G Sóczó; G Kardos; I Varga; B Kelentey; R Gesztelyi; L Majoros
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

Review 7.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms.

Authors:  Tsun Sheng N Ku; Stella M Bernardo; Samuel A Lee
Journal:  J Med Microbiol       Date:  2011-06-23       Impact factor: 2.472

Review 9.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Authors:  Maria Simitsopoulou; Pavla Peshkova; Efthymia Tasina; Aspasia Katragkou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.